|
1
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Luk JM and Liu AM: Proteomics of
hepatocellular carcinoma in Chinese patients. OMICS. 15:261–266.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lin CL and Kao JH: Risk Stratification for
hepatitis B virus related hepatocellular carcinoma. J Gastroenterol
Hepatol. 28:10–17. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gao Y, Jiang Q, Zhou X, Ding B, Wang R,
Zhao G and Chen Y: HBV infection and familial aggregation of liver
cancer: An analysis of case-control family study. Cancer Causes
Control. 15:845–850. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cabrera R, Fitian AI, Ararat M, Xu Y,
Brusko T, Wasserfall C, Atkinson MA, Liu C and Nelson DR: Serum
levels of soluble CD25 as a marker for hepatocellular carcinoma.
Oncol Lett. 4:840–846. 2012.PubMed/NCBI
|
|
7
|
Masuzaki R, Karp SJ and Omata M: New serum
markers of hepatocellular carcinoma. Semin Oncol. 39:434–439. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Marcellin P, Ziol M, Bedossa P, Douvin C,
Poupon R, de Lédinghen V and Beaugrand M: Non-invasive assessment
of liver fibrosis by stiffness measurement in patients with chronic
hepatitis B. Liver Int. 29:242–247. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
do Kim Y, Kim SU, Ahn SH, Park JY, Lee JM,
Park YN, Yoon KT, Paik YH, Lee KS, Chon CY, et al: Usefulness of
FibroScan for detection of early compensated liver cirrhosisin
chronic hepatitis B. Dig Dis Sci. 54:1758–1763. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chan HL, Wong GL, Choi PC, Chan AW, Chim
AM, Yiu KK, Chan FK, Sung JJ and Wong VW: Alanine
aminotransferase-based algorithms of liver stiffness measurement by
transient elastography (Fibroscan) for liver fibrosis in chronic
hepatitis B. J Viral Hepat. 16:36–44. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vizzutti FI, Arena U, Romanelli RG, Rega
L, Foschi M, Colagrande S, Petrarca A, Moscarella S, Belli G,
Zignego AL, et al: Liver stiffness measurement predicts severe
portal hypertension in patients with HCV-related cirrhosis.
Hepatolog. 45:1290–1297. 2007. View Article : Google Scholar
|
|
12
|
Cescon M, Colecchia A, Cucchetti A, Peri
E, Montrone L, Ercolani G, Festi D and Pinna AD: Value of transient
elastography measured with FibroScan in predicting the outcome of
hepatic resection for hepatocellular carcinoma. Ann Surg.
256:706–712; discussion 712–713. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Masuzaki R, Tateishi R, Yoshida H, Goto E,
Sato T, Ohki T, Imamura J, Goto T, Kanai F, Kato N, et al:
Prospective risk assessment for hepatocellular carcinoma
development in patients with chronic hepatitis C by transient
elastography. Hepatology. 49:1954–1961. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jung KS, Kim SU, Ahn SH, Park YN, do Kim
Y, Park JY, Chon CY, Choi EH and Han KH: Risk assessment of
hepatitis B virus-related hepatocellular carcinoma development
using liver stiffness measurement (FibroScan). Hepatology.
53:885–894. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fung J, Lai CL, Seto WK, Wong DK and Yuen
MF: Prognostic significance of liver stiffness for hepatocellular
carcinoma and mortality in HBeAg-negative chronic hepatitis B. J
Viral Hepat. 18:738–744. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chon YE, Jung ES, Park JY, do Kim Y, Ahn
SH, Han KH, Chon CY, Jung KS and Kim SU: The accuracy of
noninvasive methods in predicting the development of hepatocellular
carcinoma and hepatic decompensation in patients with chronic
hepatitis B. J Clin Gastroenterol. 46:518–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shameem M, Bhargava R, Ahmad Z, Saad T,
Fatima N and Malik A: Association between serum C-reactive protein
levels and other important predictive markers of outcome in COPD.
Acta Med Iran. 49:18–20. 2011.PubMed/NCBI
|
|
18
|
Tasxi C, Balkan A, Karadurmus N, Inal S,
Kilic S, Ozkan M, Bilgic H and Ekiz K: The importance of serum
procalcitonin levels in patients with chronic obstructive pulmonary
disease exacerbations. Turk J Med Sci. 38:139–144. 2008.
|
|
19
|
Garcia-Rio F, Miravitlles M, Soriano JB,
Muñoz L, Duran-Tauleria E, Sánchez G, Sobradillo V and Ancochea J:
EPI-SCAN Steering Committee: Systemic inflammation in chronic
obstructive pulmonary disease: A population-based study. Respir
Res. 11:632008. View Article : Google Scholar
|
|
20
|
Peisajovich A, Marnell L, Mold C and Du
Clos TW: C-reactive protein at the interface between innate
immunity and inflammation. Expert Rev Clin Immunol. 4:379–390.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dinarello CA: The acute phase response.
Cecil Textbook of Medicine (20th). Bennett JC and Plum F: WB
Saunders Co. 1535–1537. 1996.
|
|
22
|
Andreozzi P, Viscogliosi G, Colella F,
Subic M, Cipriani E, Marigliano B, Verrusio W, Servello A, Ettorre
E and Marigliano V: Predictors of liver fibrosis in patients with
non-alcoholic fatty liver disease. The role of metabolic syndrome,
insulin-resistance and inflammation. Recenti Prog Med. 103:570–574.
2012.PubMed/NCBI
|
|
23
|
Ma LN, Liu XY, Luo X, Hu YC, Liu SW, Tang
YY, Pan JL and Ding XC: Serum high-sensitivity C-reactive protein
are associated with HBV replication, liver damage and fibrosis in
patients with chronic hepatitis B. Hepatogastroenterology.
62:368–372. 2015.PubMed/NCBI
|
|
24
|
Atta M, Cabral M, Santos G, Paraná R and
Atta A: Inflammation biomarkers in chronic hepatitis C: Association
with liver histopathology, HCV genotype and cryoglobulinemia.
Inflamm Res. 61:1101–1106. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sjöwall CI, Cardell K, Boström EA,
Bokarewa MI, Enocsson H, Ekstedt M, Lindvall L, Frydén A and Almer
S: High prevalence of autoantibodies to C-reactive protein in
patients with chronic hepatitis C infection: association with liver
fibrosis and portal inflammation. Hum Immunol. 73:382–388. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nishikawa H, Arimoto A, Wakasa T, Kita R,
Kimura T and Osaki Y: Pre-treatment C-reactive protein as a
prognostic factor for recurrence after surgical resection of
hepatocellular carcinoma. Anticancer research. 33:1181–1188.
2013.PubMed/NCBI
|
|
27
|
Chen W, Wang JB, Abnet CC, Dawsey SM, Fan
JH, Yin LY, Yin J, Taylor PR, Qiao YL and Freedman ND: Association
between C-reactive protein, incident liver cancer, and chronic
liver disease mortality in the Linxian Nutrition Intervention
Trials: A nested case-control study. Cancer Epidemiol Biomarkers
Prev. 24:386–392. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao X, Luo J, Li B, Liu S and Li D: The
association between preoperative serum C-reactive protein and
hepatocellular carcinoma recurrence in patients with chronic
hepatitis B virus (HBV) infection-a retrospective study. PLoS One.
10:e01169092015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chinese Society of Hepatology and Chinese
Society of Infectious Diseases, Chinese Medical Association: The
guideline of prevention and treatment for chronic hepatitis B (2010
version). Chin J Hepatol. 19:13–24. 2011.(In Chinese).
|
